NCT04987333View on ClinicalTrials.gov

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions
Inflammatory Diseases
Interventions
DRUG

Efavaleukin alfa

Administered as a single dose SC injection.

Trial Locations (1)

LS2 9LH

Labcorp Clinical Research Unit - Leeds, Leeds

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY